Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine versus hydromorphone versus butorphanol for postoperative analgesia after VATS
ChiCTR2400082913Phase 4Not yet recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of oliceridine, hydromorphone and butorphanol in postoperative pain (3 arms), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoint: Achieving satisfactory analgesia with minimal emesis. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
oliceridinehydromorphonebutorphanol
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400082913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082913.